AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1377290 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) followed by serum PSA determination
Number of subjects: 143
Study 1377290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DRE) with 2 serum PSA determinations
Number of subjects: 143
Study 6475825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (dance exercise)
Number of subjects: 0
Study 6475825 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise
Number of subjects: 0
Study 6475825 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study 30658603 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU D2
Number of subjects: 100
Study 30658603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30658603 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU D3
Number of subjects: 100
Study 30451595 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF)
Number of subjects: 32
Study 30451595 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF therapy
Number of subjects: 32
Study 30451595 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sleep disordered breathing (SDB)
Number of subjects: 32
Study 30451595 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Disturbance Index (RDI)
Number of subjects: 32
Study 30451595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Maintenance Efficiency, Wake after Sleep Onset, REM Sleep and RDI
Number of subjects: 32
Study 27246120 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD)
Number of subjects: 580
Study 27246120 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic gastrectomy
Number of subjects: 580
Study 24911353 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine
Number of subjects: 37
Study 24911353 — intervention group
Group type: COMPARATOR
Intervention: AS01
Number of subjects: 37
Study 24911353 — intervention group
Group type: COMPARATOR
Intervention: 0.9% physiological saline
Number of subjects: 37
Study 22882105 — intervention group
Group type: EXPERIMENTAL
Intervention: School health intervention program consisting of nutrition, physical activity, behavioral knowledge and skills, and social marketing.
Number of subjects: 42
Study 22882105 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no specific intervention mentioned).
Number of subjects: 42
Study 20103722 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose celecoxib (400 mg twice daily)
Number of subjects: 204
Study 20103722 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose celecoxib (200 mg twice daily)
Number of subjects: 204
Study 20103722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 17916119 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention group (n=75)
Number of subjects: 256
Study 17916119 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention group (n=75)
Number of subjects: 256
Study 17916119 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 256
Study 17916119 — intervention group
Group type: EXPERIMENTAL
Intervention: Referred patients with major or minor depression (n=37)
Number of subjects: 256
Study 17916119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed patients (n=180)
Number of subjects: 256
Study 17505380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl iontophoretic transdermal system (ITS)
Number of subjects: 0
Study 17505380 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of morphine provided by an intravenous patient-controlled analgesia (IV PCA) pump
Number of subjects: 0
Study 15040557 — intervention group
Group type: EXPERIMENTAL
Intervention: CV8 (dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg)
Number of subjects: 165
Study 15040557 — intervention group
Group type: COMPARATOR
Intervention: Malarone (atovaquone/proguanil 3000/1200 mg)
Number of subjects: 165
Study 15040557 — intervention group
Group type: EXPERIMENTAL
Intervention: CV8
Number of subjects: 165
Study 15040557 — intervention group
Group type: COMPARATOR
Intervention: Malarone
Number of subjects: 165
Study 11315718 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy regimens (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 0
Study 9253783 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dosing of epoetin alfa
Number of subjects: 0
Study 9253783 — intervention group
Group type: COMPARATOR
Intervention: Daily dosing of epoetin alfa
Number of subjects: 0
Study 8416444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-g dose of ampicillin
Number of subjects: 84
Study 8416444 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporin (control)
Number of subjects: 84
Study 3940480 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 60 mg/d for 2 weeks, then 30 mg/d for another 2 weeks
Number of subjects: 15
Study 3940480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31225897 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐facilitated screening and brief intervention (CSBI)
Number of subjects: 965
Study 31225897 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 965
Study 28123163 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily for 21 days during acute treatment phase
Number of subjects: 0
Study 28123163 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily for up to 12 months after initial treatment
Number of subjects: 0
Study 26564581 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (STU)
Number of subjects: 29
Study 26564581 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 29
Study 25071062 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 220
Study 25071062 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 220
Study 25071062 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 220
Study 22525171 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching therapy (1 hour daily per month of age until 8 months, then 50% of waking hours)
Number of subjects: 104
Study 22525171 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching therapy
Number of subjects: 104
Study 19544315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or Nortriptyline
Number of subjects: 195
Study 17513629 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 4 g IV
Number of subjects: 200
Study 17513629 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 200
Study 15343256 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH with Ganirelix
Number of subjects: 54
Study 15343256 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH without Ganirelix
Number of subjects: 54
Study 11593124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed formula
Number of subjects: 36
Study 11593124 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 36
Study 9677506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (ALC)
Number of subjects: 334
Study 9677506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 8053025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin derivatives in combination with mefloquine for primary treatment of uncomplicated malaria
Number of subjects: 1000
Study 8053025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin derivatives for treatment of recrudescent infections
Number of subjects: 1000
Study 8053025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin derivatives for patients with high parasitaemias (> or = 4%) but no clinical evidence of severity
Number of subjects: 1000
Study 8053025 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral formulation of artemether given rectally
Number of subjects: 1000
Study 3381781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrethrins combined with piperonyl butoxide (RID)
Number of subjects: 58
Study 3381781 — intervention group
Group type: COMPARATOR
Intervention: 1% permethrin (NIX)
Number of subjects: 58
Study 3381781 — intervention group
Group type: EXPERIMENTAL
Intervention: RID comb
Number of subjects: 58
Study 31796700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback balance training for 30 min/day for 2 weeks (10 sessions)
Number of subjects: 20
Study 31796700 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training for 30 min/day for 2 weeks (10 sessions)
Number of subjects: 20
Study 28185886 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient intake (dietary monitoring)
Number of subjects: 75
Study 28185886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary monitoring with individualized feedback
Number of subjects: 75
Study 28185886 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimizing intake of macronutrients (fat and protein)
Number of subjects: 75
Study 26059002 — intervention group
Group type: EXPERIMENTAL
Intervention: WaySafe
Number of subjects: 1393
Study 26059002 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 1393
Study 23370209 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting-type calcifications
Number of subjects: 0
Study 22103965 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan coated polydioxanone sutures
Number of subjects: 750
Study 22103965 — intervention group
Group type: COMPARATOR
Intervention: Standard polydioxanone sutures
Number of subjects: 750
Study 20122026 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of primary care physicians (PCPs) in care discussions and decision-making
Number of subjects: 357
Study 20122026 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived involvement of PCPs
Number of subjects: 357
Study 20122026 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' beliefs about PCP involvement
Number of subjects: 357
Study 20122026 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in PCP involvement for older vs younger patients
Number of subjects: 357
Study 20122026 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP involvement in advanced cancer care
Number of subjects: 357
Study 17259205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 17259205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14752069 — intervention group
Group type: COMPARATOR
Intervention: Short chemotherapy (6 months)
Number of subjects: 40
Study 14752069 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chemotherapy (15 months)
Number of subjects: 40
Study 15363236 — intervention group
Group type: EXPERIMENTAL
Intervention: Autografts of patellar bone-tendon-bone (B-PT-B) and 4 strands of semitendinosus/gracilis
Number of subjects: 53
Study 15363236 — intervention group
Group type: COMPARATOR
Intervention: Allografts of B-PT-B, 4 strands of semitendinosus/2 strands of gracilis tendons, double tibialis posterior, and Achilles bone-tendon
Number of subjects: 53
Study 10691155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg t.d.s.)
Number of subjects: 75
Study 10691155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9090332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose olanzapine
Number of subjects: 335
Study 9090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 335
Study 9090332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 9090332 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10-20 mg/day)
Number of subjects: 335
Study 1439601 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 55
Study 1439601 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 55
Study 1439601 — intervention group
Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 55
Study 2945785 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1 g elemental calcium/day)
Number of subjects: 54
Study 2945785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29536776 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 60
Study 29536776 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 60
Study 29536776 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 60
Study 27762575 — intervention group
Group type: EXPERIMENTAL
Intervention: Wise deliberate practice interventions
Number of subjects: 0
Study 27762575 — intervention group
Group type: COMPARATOR
Intervention: Control condition teaching standard study skills
Number of subjects: 0
Study 27762575 — intervention group
Group type: COMPARATOR
Intervention: Control condition discussing deep interests, generalized motivation, and high achievement
Number of subjects: 0
Study 24351126 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver pairs
Number of subjects: 304
Study 24351126 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional, financial, and physical quality of life
Number of subjects: 304
Study 24351126 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and financial quality of life
Number of subjects: 304
Study 24351126 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 304
Study 24351126 — intervention group
Group type: COMPARATOR
Intervention: Solo caregivers
Number of subjects: 304
Study 23043272 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 40
Study 23043272 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (CON)
Number of subjects: 40
Study 21114221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood gas monitoring with the CDI 500
Number of subjects: 100
Study 21114221 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB blood gas management with intermittent blood gas results (Control)
Number of subjects: 100
Study 18451005 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 18451005 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0
Study 18451005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 18451005 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0
Study 18451005 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 18451005 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 0
Study 18451005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (in phase 2)
Number of subjects: 0
Study 15775951 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder by telephone
Number of subjects: 0
Study 15775951 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder by mail
Number of subjects: 0
Study 15775951 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder by SMS
Number of subjects: 0
Study 15775951 — intervention group
Group type: COMPARATOR
Intervention: No reminder (Control)
Number of subjects: 0
Study 14516890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 0
Study 14516890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day + warfarin
Number of subjects: 0
Study 14516890 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 0
Study 10332684 — intervention group
Group type: COMPARATOR
Intervention: lispro (group 2)
Number of subjects: 24
Study 10332684 — intervention group
Group type: COMPARATOR
Intervention: lispro + NPH (group 3)
Number of subjects: 24
Study 10332684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hum-R (group 1)
Number of subjects: 24
Study 8711985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 56
Study 1776541 — intervention group
Group type: EXPERIMENTAL
Intervention: Smelling a preload
Number of subjects: 0
Study 1776541 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study 6810866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithicarb (standard lithium carbonate preparation)
Number of subjects: 6
Study 6810866 — intervention group
Group type: EXPERIMENTAL
Intervention: Priadel (sustained-release lithium carbonate preparation)
Number of subjects: 6
Study 30635252 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 + 10 group (PCV10 at 6 weeks and 10 weeks of age)
Number of subjects: 304
Study 30635252 — intervention group
Group type: COMPARATOR
Intervention: 6 + 14 group (PCV10 at 6 weeks and 14 weeks of age)
Number of subjects: 304
Study 30635252 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-booster response at 10 months of age
Number of subjects: 304
Study 30635252 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 + 10 group
Number of subjects: 304
Study 30635252 — intervention group
Group type: COMPARATOR
Intervention: 6 + 14 group
Number of subjects: 304
Study 28474817 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM)
Number of subjects: 792
Study 28474817 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated DM (ITDM)
Number of subjects: 792
Study 28474817 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin-treated DM (NITDM)
Number of subjects: 792
Study 25934656 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus stenting
Number of subjects: 380
Study 25934656 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy alone
Number of subjects: 380
Study 23296149 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (mAb) therapy
Number of subjects: 15
Study 23296149 — intervention group
Group type: COMPARATOR
Intervention: CNI (Control group)
Number of subjects: 15
Study 20818996 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen cryotherapy (LN)
Number of subjects: 65
Study 20042790 — intervention group
Group type: EXPERIMENTAL
Intervention: Left arm activation training (20-30 hours)
Number of subjects: 12
Study 20042790 — intervention group
Group type: COMPARATOR
Intervention: Traditional visual scanning training (10 hours)
Number of subjects: 12
Study 20042790 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Left arm activation and Traditional visual scanning)
Number of subjects: 12
Study 20042790 — intervention group
Group type: EXPERIMENTAL
Intervention: Left arm activation training
Number of subjects: 12
Study 17896565 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/prednisone
Number of subjects: 0
Study 17896565 — intervention group
Group type: COMPARATOR
Intervention: mitoxantrone/prednisone
Number of subjects: 0
Study 17896565 — intervention group
Group type: EXPERIMENTAL
Intervention: satraplatin
Number of subjects: 0
Study 15133973 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial alignment measurement using computer tomography
Number of subjects: 50
Study 15133973 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational alignment measurement using four angles: proximal femoral, distal femoral, proximal tibial, and ankle joint angles
Number of subjects: 50
Study 12043861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical gutta-percha condensation technique
Number of subjects: 0
Study 12043861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral gutta-percha condensation technique
Number of subjects: 0
Study 12043861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study 9827976 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral r‐metHuG‐CSF (filgrastim) administered as a viscous mouthrinse (carboxymethylcellulose 2%, oleum citrii) 4 x 120 microg/day from days 10 to 16.
Number of subjects: 8
Study 9827976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 9827976 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral r‐metHuG‐CSF (filgrastim)
Number of subjects: 8
Study 7986112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with increased dose intensity
Number of subjects: 0
Study 7986112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant/neoadjuvant chemotherapy
Number of subjects: 0
Study 7986112 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant/neoadjuvant chemotherapy regimens
Number of subjects: 0
Study 2506834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy with 30 mg of Mitomycin-C (in 3 doses) and 5 mg/kg/day of 5-FU (1985-1986) or 3 mg/kg/day of 5-FU (1987-1988)
Number of subjects: 51
Study 2506834 — intervention group
Group type: COMPARATOR
Intervention: Control group with the same doses of drugs injected into the peripheral vein
Number of subjects: 51
Study 2506834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy with 5 mg/kg/day of 5-FU
Number of subjects: 51
Study 2506834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy with 3 mg/kg/day of 5-FU
Number of subjects: 51
Study 2506834 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study 1277718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium phosphate
Number of subjects: 24
Study 1277718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 1277718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate
Number of subjects: 24
Study 7304488 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of piperazine citrate administered twice within a 2-week period
Number of subjects: 185
Study 7304488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 7304488 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of piperazine citrate
Number of subjects: 185
Study 30119098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene and cosmetic products (toothpastes, dental tablets, mouthwashes, lip-balms, lipsticks)
Number of subjects: 66
Study 29443750 — intervention group
Group type: EXPERIMENTAL
Intervention: roflumilast 500 μg once daily for 12 months
Number of subjects: 120